FDAsafety guidance72% confidence
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Eli Lilly.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Hematology · IDH Inhibition
- Sub-indication
- General
Related signal: Eli Lilly initiates Phase 1 trial of oral IDH inhibitor LY3410738 in hematologic malignancies